Oddly enough, the study was sponsored by none other than Boehringer Ingelheim Pharmaceuticals.
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
(ClinicalTrials.gov number, NCT00153101 [ClinicalTrials.gov])
"Supported by a grant from Boehringer Ingelheim, the Heart and Stroke Foundation of Ontario, and a Senior Scientist Award from the Canadian Institutes of Health Research (to Dr. Yusuf)."
Who do you want to pay for it?
hi
you will find lot of information in this site
get more info from Universal Technical Institute on programs of your choice